Dr. Razelle Kurzrock is known for developing the largest phase 1 clinical trials department in the nation/world while at the University of Texas MD Anderson Cancer Center. A central theme of that program was the personalized medicine strategy, embodied in a protocol called PREDICT for Profile-related Evidence Determining Individualized Cancer Therapy. This approach utilized advanced molecular technologies to match patients with targeted cancer treatment that is more likely to work for their individual tumors.
At Moores Cancer Center, Dr. Kurzrock's charge is broad, including not just growing and innovating the center's clinical trials program, but also heading its newly established Center for Personalized Cancer Therapy. This center focuses on precision medicine trials, using the most innovative genomically-targeted drugs and/or agents that arm the immune system. As a physician-scientist, Dr. Kurzrock brings extraordinary expertise and experience in clinical research, business operations, regulatory operations, financial and budget planning, and administrative oversight, in addition to her world-recognized work in translational science. Dr. Kurzrock is also chief of the Division of Hematology and Oncology in the UC San Diego School of Medicine.
Dr. Kurzrock received her medical degree from the University of Toronto and has over 550 peer-reviewed publications and a uniquely strong record of competitive grant funding within the setting of phase I program building. She has been the principal investigator of the National Cancer Institute U01 Phase I Studies of Targeted Anti-Cancer Agents [2005 to 2012] and the inaugural CTSA grant while at University of Texas (~35 million dollars: Co-PI).
Dr. Kurzrock has four children and lives with her husband, Dr. Philip Cohen, a dermatologist, in San Diego, California.